Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 1.50 (15.789%)
Open: 10.25
High: 10.25
Low: 10.25
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Tue, 28th Apr 2020 14:43

(Alliance News) - The follow is a round-up of share dealings by London-listed company directors and managers announced on Monday and Tuesday and not separately reported by Alliance News:

----------

easyHotel PLC - Citrus Holdco Ltd, the investment vehicle of Chair Hermanus Meijer, Non-Executive Director Charles Persello, and Michael Neuman, representative of corporate director Cadim Fonds Inc, buys 183,688 shares at GBP0.70, worth GBP128,582, on Friday last week. At the start of last week, easyHotel offered an exit opportunity to minority shareholders at the same price. Citrus Holdco held 71.2% of the shares at that point, with brand-owner easyGroup having 25.8%, leaving just 3% in public hands. easyHotel plans to cancel its listing on AIM from May 19.

----------

Witan Investment Trust PLC - Non-Executive Director Gabrielle Boyle buys 28,683 shares at 173.41p, worth GBP49,739, on Monday.

----------

Scancell Holdings PLC - Non-Executive Director Martin Diggle sells 2.0 million shares via Vulpes Life Science Fund, at 8p, worth GBP160,000, on Monday and Friday last week. Vulpes now holds 78.5 million shares, a 17% stake.

----------

Manchester & London Investment Trust PLC - Investment Manager Mark Sheppard sells 58,266 shares at GBP5.62 and GBP5.66, worth GBP327,586, on Monday.

----------

Geiger Counter Ltd - Chair George Baird buys 100,000 shares at GBP0.17, worth GBP16,680, on Friday last week.

----------

Alfa Financial Software Holdings PLC - Chief Financial Officer Duncan Magrath buys 100,000 shares at GBP0.79, worth GBP79,000, on Monday.

----------

Artemis Alpha Trust PLC - Fund Manager Kartik Kumar buys 12,500 shares at GBP2.45, worth GBP30,625, on Friday last week.

----------

Jadestone Energy Inc - Non-Executive Chair Dennis McShane buys 150,732 shares at 43.02p to 44.40p, worth GBP65,337, on Friday last week and Monday. Now holds 453,651 shares.

----------

Salt Lake Potash Ltd - Chair Ian Middlemas buys 2.3 million shares, CEO Tony Swiericzuk 505,883, and CFO Shaun Day 102,941 last week, as part of company's placement of 58.8 million shares at AUD0.34 to raise AUD20.0 million. The funds will be used to deliver the Lake Way project in Western Australia. Salt Lake Potash said commissioning is expected to commence in December with first production in the first quarter of 2021.

----------

City Merchants High Yield Trust Ltd - Non-executive directors Tim Scholefield and Stuart McMaster buy 6,000 shares at 171.80p and 25,000 shares at 171.67p, respectively, on Tuesday. The purchases are together worth GBP53,000.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 Feb 2014 08:32

UK MORNING BRIEFING: Shares Open Higher But Barclays Down On Results

LONDON (Alliance News) - UK shares have opened higher Tuesday ahead of the testimony later in the day by new US Federal Reserve Chair Janet Yellen.

Barclays has said it is in a position to increase its leverage ratio target, despite a loss in its final quarter. Bar

Read more
6 Jan 2014 08:27

Scancell To Boost Moditope Team After Getting Nottingham Grant

Read more
18 Nov 2013 10:25

Scancell Gets Ichor Extension, But Agrees To Waive Options Lock In

Read more
22 Oct 2013 16:26

Prezzo exec slices off 200,000 shares

Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold t

Read more
22 Oct 2013 09:48

DIRECTOR DEALINGS: Scancell Directors Sell Shares

Read more
1 Oct 2013 10:02

Scancell reports progress across a number of trials

Scancell, which develops novel immunotherapies for the treatment of cancer, on Tuesday revealed that four out of the six evaluable patients treated with either the 2mg or 4mg dose of its SCIB1 drug still remain alive. It said the mean survival time in this group of five Stage IV and one Stage IIIb

Read more
3 Sep 2013 14:13

Scancell secures Australian patent

Scancell said it had received a patent for its DNA ImmunoBody treatment in Australia. Australia is the first jurisdiction to approve the DNA patent. Scancell said it was an important step to comprehensively protecting the technology. Scancell specialises in treatments to encourage the immune sys

Read more
3 Sep 2013 10:44

Scancell DNA Immunotherapy Technology Granted Patent In Australia

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
6 Feb 2013 11:06

Scancell shares healthy following patent approval award in Japan

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan. The same patent has already been approved in the US, Europe and Australia. Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This

Read more
31 Jan 2013 15:04

Sector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit

The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta

Read more
31 Jan 2013 14:33

Six month operating loss increases slightly at Scancell

AIM-listed medical company Scancell has published its unaudited interim results for the six month period to October 31st, showing an overall operating loss of 989,981 pounds. This compared to a loss of £941,674 in the corresponding period in 2011. The cash at bank on October 31st was £2.6m compar

Read more
29 Jan 2013 09:05

Scancell Holdings updates on clinical trial of melanoma vaccine

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection. The trial is being cond

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.